Skip to main content
Top
Published in: Heart and Vessels 4/2014

01-07-2014 | Original Article

Serum uric acid is an independent predictor of metabolic syndrome in a Japanese health screening population

Author: Eiji Oda

Published in: Heart and Vessels | Issue 4/2014

Login to get access

Abstract

Serum levels of uric acid (UA) are associated with metabolic syndrome (MetS). However, no study has been aimed to investigate whether baseline UA is a predictor of MetS in a Japanese population. The multivariable adjusted hazard ratios (HRs) of MetS through 3 years were calculated for each 1 SD increase in baseline UA, for the higher quartiles of baseline UA compared with the lowest quartile, and for baseline hyperuricemia defined as ≥7.0 mg/dl for men and ≥6.0 mg/dl for women in apparently healthy 1,606 men aged 51.7 ± 9.4 years and 953 women aged 51.6 ± 9.4 years who visited a medical check-up center in Japan. The HRs (95 % confidence interval; p value) were 1.282 (1.097–1.499; 0.002) in men and 1.354 (1.041–1.762; 0.024) in women for 1 SD increase in baseline UA, 2.206 (1.344–3.620; 0.002) in men and 3.110 (1.121–8.627; 0.029) in women for the highest quartile of baseline UA compared with the lowest quartile, and 1.900 (1.376–2.622; <0.001) in men and 2.088 (1.040–4.190; 0.038) in women for baseline hyperuricemia adjusting for the pre-existing components of MetS, age, smoking, drinking, physical activity, use of antihypertensive, antihyperlipidemic, and antidiabetic medications and histories of coronary heart disease and stroke. However, no significant association was found between longitudinal changes in UA and incident MetS. Baseline UA is an independent predictor of MetS in a Japanese health screening population.
Literature
1.
go back to reference Davis N (1897) The cardiovascular and renal relations and manifestations of gout. JAMA 29:261–262CrossRef Davis N (1897) The cardiovascular and renal relations and manifestations of gout. JAMA 29:261–262CrossRef
2.
go back to reference Gertler MM, Garn SM, Levine SA (1951) Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med 34:1421–1431PubMedCrossRef Gertler MM, Garn SM, Levine SA (1951) Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med 34:1421–1431PubMedCrossRef
3.
go back to reference Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH (1966) Hyperuricemia in primary and renal hypertension. N Engl J Med 275:457–464PubMedCrossRef Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH (1966) Hyperuricemia in primary and renal hypertension. N Engl J Med 275:457–464PubMedCrossRef
4.
go back to reference Lehto S, Niskanen L, Rönnemaa T, Laakso M (1998) Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 29:635–639PubMedCrossRef Lehto S, Niskanen L, Rönnemaa T, Laakso M (1998) Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 29:635–639PubMedCrossRef
5.
go back to reference Tuttle KR, Short RA, Johnson RJ (2001) Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol 87:1411–1414PubMedCrossRef Tuttle KR, Short RA, Johnson RJ (2001) Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol 87:1411–1414PubMedCrossRef
7.
go back to reference Siu YP, Leung KT, Tong MK, Kwan TH (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47:51–59PubMedCrossRef Siu YP, Leung KT, Tong MK, Kwan TH (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47:51–59PubMedCrossRef
8.
go back to reference Talaat KM, el-Sheikh AR (2007) The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 27:435–440PubMedCrossRef Talaat KM, el-Sheikh AR (2007) The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 27:435–440PubMedCrossRef
9.
go back to reference Ford ES, Li C, Cook S, Choi HK (2007) Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 115:2526–2532PubMedCrossRef Ford ES, Li C, Cook S, Choi HK (2007) Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 115:2526–2532PubMedCrossRef
10.
go back to reference Nakagawa T, Tuttle KR, Short RA, Johnson RJ (2005) Fructose-induced hyperuricemia as a casual mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol 1:80–86PubMedCrossRef Nakagawa T, Tuttle KR, Short RA, Johnson RJ (2005) Fructose-induced hyperuricemia as a casual mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol 1:80–86PubMedCrossRef
11.
go back to reference Culleton BF, Larson MG, Kannel WB, Levy D (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 131:7–13PubMedCrossRef Culleton BF, Larson MG, Kannel WB, Levy D (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 131:7–13PubMedCrossRef
12.
go back to reference Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560–2572PubMedCrossRef Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560–2572PubMedCrossRef
13.
go back to reference Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA (2002) AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 106:388–391PubMedCrossRef Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA (2002) AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 106:388–391PubMedCrossRef
14.
go back to reference Niskanen LK, Laaksonen DE, Nyyssönen K, Alfthan G, Lakka HM, Lakka TA, Salonen JT (2004) Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 164:1546–1551PubMedCrossRef Niskanen LK, Laaksonen DE, Nyyssönen K, Alfthan G, Lakka HM, Lakka TA, Salonen JT (2004) Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 164:1546–1551PubMedCrossRef
15.
go back to reference Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971–1992. JAMA 283:2404–2410PubMedCrossRef Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971–1992. JAMA 283:2404–2410PubMedCrossRef
16.
go back to reference Alderman MH, Cohen H, Madhavan S, Kivlighn S (1999) Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 34:144–150PubMedCrossRef Alderman MH, Cohen H, Madhavan S, Kivlighn S (1999) Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 34:144–150PubMedCrossRef
17.
go back to reference Niskanen L, Laaksonen DE, Lindström J, Eriksson JG, Keinänen-Kiukaanniemi S, Ilanne-Parikka P, Aunola S, Hämäläinen H, Tuomilehto J, Uusitupa M (2006) Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: the Finnish Diabetes Prevention Study. Diabetes Care 29:709–711PubMedCrossRef Niskanen L, Laaksonen DE, Lindström J, Eriksson JG, Keinänen-Kiukaanniemi S, Ilanne-Parikka P, Aunola S, Hämäläinen H, Tuomilehto J, Uusitupa M (2006) Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: the Finnish Diabetes Prevention Study. Diabetes Care 29:709–711PubMedCrossRef
18.
go back to reference Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S (2004) Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 44:642–650PubMedCrossRef Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S (2004) Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 44:642–650PubMedCrossRef
19.
go back to reference Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S (2001) Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 24:691–697PubMedCrossRef Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S (2001) Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 24:691–697PubMedCrossRef
20.
go back to reference Tomita M, Mizuno S, Yamanaka H, Hosoda Y, Sakuma K, Matuoka Y, Odaka M, Yamaguchi M, Yosida H, Morisawa H, Murayama T (2000) Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 10:403–409PubMedCrossRef Tomita M, Mizuno S, Yamanaka H, Hosoda Y, Sakuma K, Matuoka Y, Odaka M, Yamaguchi M, Yosida H, Morisawa H, Murayama T (2000) Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 10:403–409PubMedCrossRef
21.
go back to reference Alper AB Jr, Chen W, Yau L, Srinivasan SR, Berenson GS, Hamm LL (2005) Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension 45:34–38PubMedCrossRef Alper AB Jr, Chen W, Yau L, Srinivasan SR, Berenson GS, Hamm LL (2005) Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension 45:34–38PubMedCrossRef
22.
go back to reference Forman JP, Choi H, Curhan GC (2007) Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol 18:287–292PubMedCrossRef Forman JP, Choi H, Curhan GC (2007) Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol 18:287–292PubMedCrossRef
23.
go back to reference Krishnan E, Kwoh CK, Schumacher HR, Kuller L (2007) Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 49:298–303PubMedCrossRef Krishnan E, Kwoh CK, Schumacher HR, Kuller L (2007) Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 49:298–303PubMedCrossRef
24.
go back to reference Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML (2003) Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 42:474–480PubMedCrossRef Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML (2003) Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 42:474–480PubMedCrossRef
25.
go back to reference Mellen PB, Bleyer AJ, Erlinger TP, Evans GW, Nieto FJ, Wagenknecht LE, Wofford MR, Herrington DM (2006) Serum uric acid predicts incident hypertension in a biethnic cohort: the Atherosclerosis Risk in Communities study. Hypertension 48:1037–1042PubMedCrossRef Mellen PB, Bleyer AJ, Erlinger TP, Evans GW, Nieto FJ, Wagenknecht LE, Wofford MR, Herrington DM (2006) Serum uric acid predicts incident hypertension in a biethnic cohort: the Atherosclerosis Risk in Communities study. Hypertension 48:1037–1042PubMedCrossRef
26.
go back to reference Nagahama K, Inoue T, Iseki K, Touma T, Kinjo K, Ohya Y, Takishita S (2004) Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res 27:835–841PubMedCrossRef Nagahama K, Inoue T, Iseki K, Touma T, Kinjo K, Ohya Y, Takishita S (2004) Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res 27:835–841PubMedCrossRef
27.
go back to reference Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K (2003) Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol 18:523–530PubMedCrossRef Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K (2003) Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol 18:523–530PubMedCrossRef
28.
go back to reference Perlstein TS, Gumieniak O, Williams GH, Sparrow D, Vokonas PS, Gaziano M, Weiss ST, Litonjua AA (2006) Uric acid and the development of hypertension: the Normative Aging Study. Hypertension 48:1031–1036PubMedCrossRef Perlstein TS, Gumieniak O, Williams GH, Sparrow D, Vokonas PS, Gaziano M, Weiss ST, Litonjua AA (2006) Uric acid and the development of hypertension: the Normative Aging Study. Hypertension 48:1031–1036PubMedCrossRef
29.
go back to reference Sundström J, Sullivan L, D’Agostino RB, Levy D, Kannel WB, Vasan RS (2005) Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 45:28–33PubMedCrossRef Sundström J, Sullivan L, D’Agostino RB, Levy D, Kannel WB, Vasan RS (2005) Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 45:28–33PubMedCrossRef
30.
go back to reference Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fujii S, Okada K (2001) Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: the Osaka Health Survey. J Hypertens 19:1209–1215PubMedCrossRef Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fujii S, Okada K (2001) Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: the Osaka Health Survey. J Hypertens 19:1209–1215PubMedCrossRef
31.
go back to reference Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC (2008) High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 31:361–362PubMedCrossRef Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC (2008) High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 31:361–362PubMedCrossRef
32.
go back to reference Quiñones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, Ferrannini E (1995) Effect of insulin on uric acid excretion in humans. Am J Physiol 268:E1–E5PubMed Quiñones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, Ferrannini E (1995) Effect of insulin on uric acid excretion in humans. Am J Physiol 268:E1–E5PubMed
33.
go back to reference Carnethon MR, Fortmann SP, Palaniappan L, Duncan BB, Schmidt MI, Chambless LE (2003) Risk factors for progression to incident hyperinsulinemia: the Atherosclerosis Risk in Communities Study, 1987–1998. Am J Epidemiol 158:1058–1067PubMedCrossRef Carnethon MR, Fortmann SP, Palaniappan L, Duncan BB, Schmidt MI, Chambless LE (2003) Risk factors for progression to incident hyperinsulinemia: the Atherosclerosis Risk in Communities Study, 1987–1998. Am J Epidemiol 158:1058–1067PubMedCrossRef
34.
go back to reference Chien KL, Chen MF, Hsu HC, Chang WT, Su TC, Lee YT, Hu FB (2008) Plasma uric acid and the risk of type 2 diabetes in a Chinese community. Clin Chem 54:310–316PubMedCrossRef Chien KL, Chen MF, Hsu HC, Chang WT, Su TC, Lee YT, Hu FB (2008) Plasma uric acid and the risk of type 2 diabetes in a Chinese community. Clin Chem 54:310–316PubMedCrossRef
35.
go back to reference Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, Johnson RJ (2006) A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 290:F625–F631PubMedCrossRef Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, Johnson RJ (2006) A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 290:F625–F631PubMedCrossRef
36.
go back to reference Sánchez-Lozada LG, Tapia E, Bautista-García P, Soto V, Avila-Casado C, Vega-Campos IP, Nakagawa T, Zhao L, Franco M, Johnson RJ (2008) Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 294:F710–F718PubMedCrossRef Sánchez-Lozada LG, Tapia E, Bautista-García P, Soto V, Avila-Casado C, Vega-Campos IP, Nakagawa T, Zhao L, Franco M, Johnson RJ (2008) Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 294:F710–F718PubMedCrossRef
37.
go back to reference Reungjui S, Roncal CA, Mu W, Srinivas TR, Sirivongs D, Johnson RJ, Nakagawa T (2007) Thiazide diuretics exacerbate fructose-induced metabolic syndrome. J Am Soc Nephrol 18:2724–2731PubMedCrossRef Reungjui S, Roncal CA, Mu W, Srinivas TR, Sirivongs D, Johnson RJ, Nakagawa T (2007) Thiazide diuretics exacerbate fructose-induced metabolic syndrome. J Am Soc Nephrol 18:2724–2731PubMedCrossRef
38.
go back to reference Onat A, Uyarel H, Hergenç G, Karabulut A, Albayrak S, Sari I, Yazici M, Keleş I (2006) Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens 19:1055–1062PubMedCrossRef Onat A, Uyarel H, Hergenç G, Karabulut A, Albayrak S, Sari I, Yazici M, Keleş I (2006) Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens 19:1055–1062PubMedCrossRef
39.
go back to reference Lohsoonthorn V, Dhanamun B, Williams MA (2006) Prevalence of hyperuricemia and its relationship with metabolic syndrome in Thai adults receiving annual health exams. Arch Med Res 37:883–889PubMedCrossRef Lohsoonthorn V, Dhanamun B, Williams MA (2006) Prevalence of hyperuricemia and its relationship with metabolic syndrome in Thai adults receiving annual health exams. Arch Med Res 37:883–889PubMedCrossRef
40.
go back to reference Choi HK, Ford ES (2007) Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 120:442–447PubMedCrossRef Choi HK, Ford ES (2007) Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 120:442–447PubMedCrossRef
41.
go back to reference Liu PW, Chang TY, Chen JD (2010) Serum uric acid and metabolic syndrome in Taiwanese adults. Metabolism 59:802–807PubMedCrossRef Liu PW, Chang TY, Chen JD (2010) Serum uric acid and metabolic syndrome in Taiwanese adults. Metabolism 59:802–807PubMedCrossRef
42.
go back to reference Ryu S, Song J, Choi BY, Lee SJ, Kim WS, Chang Y, Kim DI, Suh BS, Sung KC (2007) Incidence and risk factors for metabolic syndrome in Korean male workers, ages 30–39. Ann Epidemiol 17:245–252PubMedCrossRef Ryu S, Song J, Choi BY, Lee SJ, Kim WS, Chang Y, Kim DI, Suh BS, Sung KC (2007) Incidence and risk factors for metabolic syndrome in Korean male workers, ages 30–39. Ann Epidemiol 17:245–252PubMedCrossRef
43.
go back to reference Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN (2008) Uric acid and the development of metabolic syndrome in women and men. Metabolism 57:845–852PubMedCentralPubMedCrossRef Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN (2008) Uric acid and the development of metabolic syndrome in women and men. Metabolism 57:845–852PubMedCentralPubMedCrossRef
44.
go back to reference Gonçalves JP, Oliveira A, Severo M, Santos AC, Lopes C (2012) Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome. Endocrine 41:450–457PubMedCrossRef Gonçalves JP, Oliveira A, Severo M, Santos AC, Lopes C (2012) Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome. Endocrine 41:450–457PubMedCrossRef
45.
go back to reference Yang T, Chu CH, Bai CH, You SL, Chou YC, Chou WY, Chien KL, Hwang LC, Su TC, Tseng CH, Sun CA (2012) Uric acid level as a risk marker for metabolic syndrome: a Chinese cohort study. Atherosclerosis 220:525–531PubMedCrossRef Yang T, Chu CH, Bai CH, You SL, Chou YC, Chou WY, Chien KL, Hwang LC, Su TC, Tseng CH, Sun CA (2012) Uric acid level as a risk marker for metabolic syndrome: a Chinese cohort study. Atherosclerosis 220:525–531PubMedCrossRef
46.
go back to reference Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, American Heart Association, National Heart, Lung, and Blood Institute (2005) Diagnosis and management of the metabolic syndrome: a statement for health care professionals: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752PubMedCrossRef Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, American Heart Association, National Heart, Lung, and Blood Institute (2005) Diagnosis and management of the metabolic syndrome: a statement for health care professionals: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752PubMedCrossRef
47.
go back to reference Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr, International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity (2009) Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645PubMedCrossRef Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr, International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity (2009) Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645PubMedCrossRef
48.
go back to reference Alberti KGMM, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 223:469–480CrossRef Alberti KGMM, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 223:469–480CrossRef
49.
go back to reference Oda E (2012) Metabolic syndrome: its history, mechanisms, and limitations. Acta Diabetol 49:89–95PubMedCrossRef Oda E (2012) Metabolic syndrome: its history, mechanisms, and limitations. Acta Diabetol 49:89–95PubMedCrossRef
50.
go back to reference Choi HK, Ford ES (2007) Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 120:442–447PubMedCrossRef Choi HK, Ford ES (2007) Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 120:442–447PubMedCrossRef
51.
go back to reference Saito T, Mochizuki T, Uchida K, Tsuchiya K, Nitta K (2012) Metabolic syndrome and risk of progression of chronic kidney disease: a single-center cohort study in Japan. Heart Vessels. doi:10.1007/s00380-012-0254-5 Saito T, Mochizuki T, Uchida K, Tsuchiya K, Nitta K (2012) Metabolic syndrome and risk of progression of chronic kidney disease: a single-center cohort study in Japan. Heart Vessels. doi:10.​1007/​s00380-012-0254-5
52.
go back to reference Nishino M, Mori N, Yoshimura T, Nakamura D, Lee Y, Taniike M, Makino N, Kato H, Egami Y, Shutta R, Tanouchi J, Yamada Y (2013) Higher serum uric acid and lipoprotein(a) are correlated with coronary spasm. Heart Vessels. doi:10.1007/s00380-013-0346-x Nishino M, Mori N, Yoshimura T, Nakamura D, Lee Y, Taniike M, Makino N, Kato H, Egami Y, Shutta R, Tanouchi J, Yamada Y (2013) Higher serum uric acid and lipoprotein(a) are correlated with coronary spasm. Heart Vessels. doi:10.​1007/​s00380-013-0346-x
Metadata
Title
Serum uric acid is an independent predictor of metabolic syndrome in a Japanese health screening population
Author
Eiji Oda
Publication date
01-07-2014
Publisher
Springer Japan
Published in
Heart and Vessels / Issue 4/2014
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-013-0386-2

Other articles of this Issue 4/2014

Heart and Vessels 4/2014 Go to the issue